1. Corneli A, Field S, Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J and Guest G. Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. *PloS One 2015*; DOI:10.1371/journal.pone.0129177.

2. Kelly CA, Friedland BA, Morar NS, Katzen LL, Ramjee G, Mokgatle MM and Ahmed K. Tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa. *Culture, Health & Sexuality 2015*. DOI: 10.1080/13691058.2015.1030451.

3. Agot K, Taylor D, Corneli A, Wang M, Ambia J, Kashuba A, Parker C, Lemons A, Malahleha M, Lombaard J, Van Damme L. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. *AIDS Behav. 2015*; 19 (5): 743-751.

4. Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F and Van Damme L. Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. *Plos One 2015*. DOI:10.1371/journal.pone.0125458.

5. Corneli A L, McKenna K, Perry B, Ahmed K, Ago K, Malamatsho F, Skhosana J, Odhiambo J, Van Damme L. The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills. *J Acquired Immune Deficiency Syndrome 2015*; 68 (5): 578-584.

6. Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, Ahmed K, Skhosana J, Ratlhagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L. Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial. *Open Access Journal of clinical Trials 2015*; 7: 1-9.

7. Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D, for the FEM-PrEP Study Group. Pregnancy and Contraceptive Use Among Women Participating in the FEM-PrEP Trial. *Acquir Immune Defic. Syndr 2015*; 68 (2): 196 – 203.
8. Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D and Van Damme L. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. **BMC Pharmacology and Toxicology 2014;** 15 (1): 77.

9. Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, for the FEM-PrEP Study Group. Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP. **Journal of Acquired Immune Deficiency Syndromes 2014;** 67 (5): 455-575.

10. Corneli AL, McKenna K, Headley J, Ahmed K, Odhiambo J, Skhosana J, Wang M and Agot K for the FEM-PrEP Study Group. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa **Journal of the International AIDS Society 2014,** 17 (Suppl 2): 19152

11. Evens E, Tolley E, Headley J, McCragher D, Hartmann M, Mtimkulu VT, Manenzhe K, Hamela G, Zulu F. Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi. **Culture, Health and Sexuality 2014;** 29: 1-16.

12. Grant R.M, Liegler T, Defechreux P, Kashuba A.D.M, Taylor D, Abdel-Mohsen M., Deese J, Fransen K, De Baetselier I, Cricitti T, Bentley G, Agingu W, Ahmed K and Van Damme L. Drug resistance and plasma viral RNA level after ineffective use of pre-exposure prophylaxis in Women. **AIDS 2014;** 29 (3): 331-337.

13. Headly J, Corneli A., Agot K, Ahmed K, Wang M, Odhiambo J, Skhosana J, Tharaldson J, van Damme L, MacQueen K, For the FEM-PrEP Study Group. The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. **PloS One 2014;** 17: 9 (9).

14. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Monangi R, Kapiga S, Kashuba A and van Damme L, for the FEM-PrEP Study Group. FEM-PEP Adherence Patterns
and Factors Associated with Adherence to a Daily oral Study Product for Pre-exposure Prophylaxis. *Journal of Acquired Immune Deficiency Syndromes* 2014; 66 (3): 324-331.

15. Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, **Ahmed K**, Rathlagana MJM, Mthembu PN, and Ngcozela N. Enrollment of Adolescents Aged 16-17 Years Old in Microbicide Trials: An Evidence-Based Approach. *Journal of Adolescent Health* 2014; 54 (6): 654-662.

16. **Malahleha M**, Mokwena K, **Ahmed K**. Knowledge and Perceptions of Vaginal Microbicides among Healthcare Postgraduate Students at the University of Limpopo. *AIDS Res Hum Retroviruses* 2014; 30 (S1): A163-A164.

17. Mack N, Kirkendale S, Omullo P, Odhiambo J, Masiki M, Siguntu P, Ratlhagana M, Agot K, **Ahmed K**, Kapiga S, Lombaard J, van Damme L, Corneli A. Implementing good participatory practice guidelines in the FEM-PrEP Preexposure Profilaxis Trial for HIV Prevention Among African Women: a focus on local stakeholder involvement. *Journal of clinical Trials* 2013; 5:127-135.

18. **Ahmed K**, Malahleha M, Deese J, Monedi C and van Damme L. Elevated liver transaminases, human immune deficiency virus (HIV) seroconversion and rapid progression to AIDS in a HIV prevention clinical trial participant: A case report *Journal of AIDS and HIV Research* 2013; 5 (3): 65-69.

19. Van Damme L, Corneli A, **Ahmed K**, Agot K, Lombaard J, Kapiga S, **Malahleha M** al. Pre-exposure prophylaxis for HIV infection among African women. *The New England Journal of Medicine* 2012; 367: 411-422.

20. Morrison C, Skoler-Karpoff S, Kwoka C, Chena P L, Wijgert J, Gehret-Plagianos MPatel S, Ahmed K, et al. Hormonal Contraception and the Risk of HIV Acquisition among Women in South Africa. *AIDS* 2012; 4: 497-504.

21. Marais Gawarecki D, Allan B, **Ahmed K**, Altini L, **Cassim N**, Gopaleng F, Hoffman M, Ramjee G, Williamson A-L. The Effectiveness of Carraguard, a Vaginal Microbicide, in protecting
women against high-risk Human Papilloma-Virus infection. *Antiviral therapy* 2011; 16 (8): 1219-1226.

22. Mensch BS, Hewett PC, Abbott S, Rankin J, Littlefield S, Ahmed K, Cassim N, Patel S, Ramjee G, Palanee T, Mierzwa S, Skoler-Karpoff S. Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel. *AIDS and Behaviour* 2011; 15: 407-421.

23. Said HM, Ahmed K, Burnett R, Allan BR, Williamson A-L, Hoosen, AA. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community based Microbicide study in Pretoria, South Africa. *Journal of Clinical Virology* 2009; 44: 318-321.

24. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, GehretPlagianos M, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial. *Lancet* 2008. 372:1977-1987.

25. Ahmed K, Cassim N. HIV prevention using vaginal microbicides: an update. *JIMASA* 2007; 14: 11-14.

26. de Kock A, Skoler S, Ahmed K, Govender S. Enrolling Adolescents in Research on HIV: Young Women Must Be Included. *PLoS Med* 2006; 3 (12): 2458-2463.

27. Skoler S, Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P, Fleming Richardson B. Risks in the use of an unblinded-control group. *Journal of Infectious Diseases* 2005; 191: 1378-1380.

28. Skoler S, Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P. Control Groups in Microbicide Trials: In defense of Orthodoxy. Correspondence Article. *Journal of Infectious Diseases* 2005; 191: 1378-1379.